Tupy (TUPY3) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
14 Jan, 2026Executive summary
Achieved record operating cash flow despite a 7% YoY revenue decline, with efficiency gains and favorable FX partially offsetting lower volumes, especially in foreign markets.
Gross margin improved to 17.9% due to operational efficiencies and FX; adjusted EBITDA margin was 12.2% despite restructuring costs.
New product launches, aftermarket, bioplant, and battery recycling initiatives advanced, driving record revenues in these segments.
Strategic focus on double-digit growth in new markets with higher margins, leveraging brand and synergies from acquisitions.
Management continues cost reduction, process optimization, and production transfer to lower-cost units, targeting further benefits by 2026.
Financial highlights
Net revenue was R$2.8B in 3Q24, down 7% YoY; gross profit R$496M, margin 17.9%; adjusted EBITDA R$338M, margin 12.2%.
Net income for 3Q24 was R$50M, impacted by higher financial expenses and FX; 9M24 net income was R$180M, down 50% YoY.
Operating cash flow for 9M24 reached a record R$762M, up 97% YoY.
Cost of goods sold decreased 7% YoY; gross margin rose by 0.3pp to 17.9%.
Net debt at R$2.3B (1.81x LTM EBITDA); cash and equivalents at R$2.92B as of September 2024.
Outlook and guidance
Positive outlook for 2025, with expected recovery in heavy-duty vehicle markets and domestic production projected to rebound by 32%, though still below 2021-2022 levels.
New business initiatives in bioplants, battery recycling, and alternative fuel engines expected to contribute significantly over the next 3-5 years.
Management expects further cost and efficiency benefits by 2026 from ongoing restructuring and production transfer.
Anticipates positive impact on US transportation and infrastructure sectors from recent US election results.
New contracts and business lines to start operations in coming months, supporting diversification.
Latest events from Tupy
- Record EBITDA and cash flow offset lower revenue; new contracts and bioplants drive growth.TUPY3
Q2 20242 Feb 2026 - Record EBITDA and cash flow achieved despite lower sales, with margin gains and strong outlook.TUPY3
Q4 202423 Dec 2025 - Revenue fell 6% and EBITDA margin dropped, but net income rose 33% on financial gains.TUPY3
Q2 202523 Nov 2025 - Revenue down 4% and net loss, but aftermarket and gensets segments showed strong growth.TUPY3
Q1 202520 Nov 2025 - Revenue and EBITDA fell, but record cash flow and new segments support future margin gains.TUPY3
Q3 202513 Nov 2025